When immunotherapy bleeds: severe hemorrhagic gastritis secondary to pembrolizumab

Authors

  • Jameel Alp Department of Medicine, University of Minnesota, Minneapolis, MN https://orcid.org/0009-0008-3761-9743
  • Rahul Karna Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Minnesota, Minneapolis, MN, USA
  • Khalid Amin Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA
  • Joshua A Sloan Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Minnesota, Minneapolis, MN, USA

DOI:

https://doi.org/10.15403/jgld-6324

Keywords:

pembrolizumab, gastritis, Immune-related adverse events, hematemesis

Downloads

Published

2025-09-26

How to Cite

1.
Alp J, Karna R, Amin K, Sloan JA. When immunotherapy bleeds: severe hemorrhagic gastritis secondary to pembrolizumab. JGLD [Internet]. 2025 Sep. 26 [cited 2026 Apr. 26];34(3):413-4. Available from: https://jgld.ro/jgld/index.php/jgld/article/view/6324

Issue

Section

Letters